Need help here, RVX is a participant in COVID 19 trail as companion drug using only Type 2 patients.  It is known Type 2 patients have greater ACE2 receptors (not good) and Apabetalone inhibits ACE2.  Does anyone know when the trial will begin?  It should not take long to determine if Apabetalone is beneficial.  Knowing that COVID 19 patients are increasing daily seems the world would benefit greatly if current test is positive with companion Apabetalone.  Seems many Type 2 would begin seeking daily doses just to prevent or minimize the effects of COVID 19.  Prevention is big.

Think about this, just in the US there are 30 M Type 2 with a million new patients each year.  COVID 19 could turn into a block buster for RVX.  Only need 5 M taking daily doses.  This would certainly give BP an incentive to leap, not just a step forward.

Now think about adding Europe, Canada, all countries.  Big numbers here.

Let’s see, 5M taking two doses daily x 365, believe this runs into money.  Believe this is the point of the test. I could be all wrong, so please help me. Still believe in holding. THX.  A Believer. Sidebar.  PS, we should know soon, September or October?